Dr. Bander is the inventor on patents that are owned by Cornell Research Foundation ("CRF") for the antibody technology described in this release. He is a paid consultant to and owns stock in BZL Biologics, the company to which the patents were licensed by CRF for further research and development.
PSMA has been an attractive target for cancer drug development not only because it is present in high amounts in prostate cancers, but it also is the only known molecular target present on tumor blood vessels that is not present on normal blood vessels. The ability to target PSMA on blood vessels provides a way to directly attack a tumor's blood supply without affecting normal blood vessels.
"Nanotechnology has the potential to cure men with advanced prostate cancer without exposing them to severe side effects," says Mr. Koch, who is a survivor of the disease, along with his three brothers. "The scientific team assembled for this work is the best in the business, and if it is possible for any group to be successful in the development of this therapy, it will be this one."
A unique aspect of the collaboration is that all institutions have agreed to share their intellectual property in order to avoid bottlenecks and barriers to patentability that could potentially impede any advancements.
"I very much look forward to working closely with the nation's leading investigators in the field of nanomedicine to create targeted nanoparticles that can deliver drugs to tumor sites," says Dr. Bander.
The four principal investigators, each leaders in their respective fields, were selected by the Prostate Cancer Foundation and David H.
|Contact: Andrew Klein|
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College